Pluri Inc.

PLUR Nasdaq CIK: 0001158780

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Country Israel
Business Address MATAM ADVANCED TECHNOLOGY PARK, HAIFA, ,
Mailing Address MATAM ADVANCED TECHNOLOGY PARK, HAIFA, ,
Phone 972-74-710-7171
Fiscal Year End 0630
EIN 980351734

Financial Overview

FY2025

-$20.89M
Net Income
$39.53M
Total Assets
$96K
Stockholders' Equity
$-3.56
EPS

Recent SEC Filings

Form Type Date Filed Document
10-Q Quarterly financial report February 12, 2026 View on SEC
8-K Current report of material events January 22, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment January 5, 2026 View on SEC
4 Insider stock transaction report January 5, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment December 15, 2025 View on SEC
8-K Current report of material events December 9, 2025 View on SEC
4 Insider stock transaction report December 8, 2025 View on SEC
4 Insider stock transaction report December 8, 2025 View on SEC
4 Insider stock transaction report December 8, 2025 View on SEC
4 Insider stock transaction report December 8, 2025 View on SEC

Annual Reports

10-K September 17, 2025
  • Progressed lung injury treatment toward FDA trials
  • Partnered with Ukraine’s Hemafund for radiation therapy drug PLX-R18
View Analysis

Material Events

8-K Financial Distress January 22, 2026
High Impact
  • Pluri Inc. received a Nasdaq delisting warning on January 20, 2026, for failing multiple listing standards.
  • The company's Market Value of Listed Securities (MVLS) is $20 million, significantly below the Nasdaq's $35 million requirement.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.